HPC
VRTX icon

HM Payson & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

HM Payson & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Hold
2,052
– – 0.01% 225
2026
Q1 		$916K Sell
2,052
-51
-2% -$23.8K 0.01% 235
2025
Q4 		$953K Sell
2,103
-30
-1% -$12.9K 0.01% 228
2025
Q3 		$835K Sell
2,133
-65
-3% -$27.2K 0.01% 234
2025
Q2 		$978K Sell
2,198
-3,623
-62% -$1.67M 0.02% 216
2025
Q1 		$2.82M Sell
5,821
-914
-14% -$426K 0.05% 135
2024
Q4 		$2.71M Sell
6,735
-340
-5% -$158K 0.05% 134
2024
Q3 		$3.29M Sell
7,075
-12,330
-64% -$5.92M 0.06% 131
2024
Q2 		$9.1M Buy
19,405
+17,389
+863% +$7.55M 0.17% 79
2024
Q1 		$843K Sell
2,016
-6
-0.3% -$2.54K 0.02% 224
2023
Q4 		$823K Buy
2,022
+1,975
+4,202% +$730K 0.02% 224
2023
Q3 		$16.3K Buy
47
+25
+114% +$8.74K ﹤0.01% 763
2023
Q2 		$7.74K Hold
22
– – ﹤0.01% 822
2023
Q1 		$6.93K Buy
+22
New +$6.6K ﹤0.01% 832
2022
Q4 		– Sell
-12
Closed -$3K – 1004
2022
Q3 		$3K Sell
12
-3
-20% -$863 ﹤0.01% 894
2022
Q2 		$4K Buy
15
+3
+25% +$803 ﹤0.01% 918
2022
Q1 		$3K Buy
+12
New +$2.85K ﹤0.01% 955
2021
Q4 		– Sell
-35
Closed -$6K – 1173
2021
Q3 		$6K Buy
+35
New +$6.83K ﹤0.01% 892
2021
Q2 		– Sell
-107
Closed -$23K – 1184
2021
Q1 		$23K Sell
107
-37
-26% -$8.13K ﹤0.01% 728
2020
Q4 		$34K Hold
144
– – ﹤0.01% 687
2020
Q3 		$39K Hold
144
– – ﹤0.01% 603
2020
Q2 		$42K Hold
144
– – ﹤0.01% 552
2020
Q1 		$34K Hold
144
– – ﹤0.01% 551
2019
Q4 		$32K Hold
144
– – ﹤0.01% 652
2019
Q3 		$24K Sell
144
-47
-25% -$8.31K ﹤0.01% 701
2019
Q2 		$35K Buy
+191
New +$33.4K ﹤0.01% 658

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

HM Payson & Co's VRTX Position: Q2 2026 in Review

HM Payson & Co held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 2,052 shares worth $1.02M. The position accounts for 0.01% of the portfolio, ranked #225.

HM Payson & Co first reported a position in VRTX in Q2 2019 and has held it in 26 quarters since. The position peaked at $9.1M in Q2 2024. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • HM Payson & Co held 2,052 shares of Vertex Pharmaceuticals worth $1.02M as of Q2 2026.
  • HM Payson & Co left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.01% of HM Payson & Co's portfolio in Q2 2026, its #225 holding.
  • HM Payson & Co first reported a position in Vertex Pharmaceuticals in Q2 2019 and has held it in 26 quarters since.
  • HM Payson & Co's Vertex Pharmaceuticals position peaked at $9.1M in Q2 2024.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on HM Payson & Co's 13F filing for Q2 2026, filed 17 Jul 2026.